Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled trial to determine the optimal dose
and safety of oral alanyl-glutamine between 4, 24, and 44 g doses administered for 10 days
with standard therapy among first time incident cases of uncomplicated C. difficile infection
(CDI) in hospitalized persons aged 65 or older. Our hypothesis is that alanyl-glutamine
supplementation will decrease recurrence and mortality from CDI and these outcomes will be
associated with improvement of inflammatory markers and restoration of intestinal microbiota
function.